RedHill Biopharma announces last patient out for phase 2/3 COVID-19 study of oral Opaganib

(RedHill Biopharma) RedHill Biopharma Ltd. (Nasdaq: RDHL), a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840). Top-line results are expected in the coming weeks.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news